Dana-Farber Review Finds Carboplatin Rationing Errors
A study shows the Boston center's 2023 drug allocation policy frequently deviated from practice during a supply shortage.
Updated on Oct. 20, 2026 in Cancer
Live Poll
Do you trust hospitals to follow their own ethical policies when rationing scarce medical treatments?
A study published on October 19, 2026, reveals that Dana-Farber Cancer Institute faced significant discrepancies in carboplatin allocation during a shortage that began on June 1, 2023. Researchers found that 26% of drug distribution decisions did not align with the center's established rationing policy.
Why it matters
The analysis highlights systemic vulnerabilities in medical resource allocation when supply chain disruptions force difficult clinical choices. It underscores the challenges major institutions face in maintaining equitable treatment standards when life-saving medications become scarce due to manufacturer production failures.
The audit of 483 records showed that 9% of low-priority patients received the drug while 28% of high-priority candidates were denied it. Additionally, 43% of patients missing a recorded category received carboplatin despite the rationing criteria.
The players
Dana-Farber Cancer Institute
This Boston-based cancer research and treatment center is a principal teaching affiliate of Harvard Medical School.
FDA
The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety and availability of drugs.
The details
Reviewers reassessed patient medical records more than two years after the shortage concluded to determine if triage categories were followed. Disparities emerged based on demographics and location, as men were more likely to receive the drug than women, and patients at the main Boston campus were favored over those at regional sites.
Timeline
June 1, 2023: Dana-Farber began rationing carboplatin.
July 17, 2023: Dana-Farber ended carboplatin rationing.
October 19, 2026: Study published in JAMA Network Open.
Health Landscape
This study follows the data tracked in the FDA drug shortages database and extends findings on generic drug market instability. The research marks a departure from standard clinical reporting by quantifying specific patient access failures during the 2023 shortage.
Patients may face unpredictable access to critical medications when manufacturing issues trigger widespread medical shortages. This study suggests that institutional tracking systems are vital for ensuring that priority-based treatment policies are applied consistently to all patients.
The takeaway
Healthcare systems often struggle to maintain equitable care protocols when external supply chains collapse. Patients should advocate for clear communication from providers regarding treatment prioritization when essential medications are in short supply.
Further reading
Find more local reports on oncology services at the Boston Cancer section.
More information
Review current supply status through the FDA drug shortages database.
Source note: This article includes information reported by Medical Daily.
Live Poll
Do you trust hospitals to follow their own ethical policies when rationing scarce medical treatments?
